Response to pemetrexed chemotherapy in lung adenocarcinoma- bronchioloalveolar carcinoma insensitive to erlotinib

Keyphrases

• Chemotherapy 100%
• Pemetrexed 100%
• Lung Adenocarcinoma 100%
• Erlotinib 100%
• Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI) 100%
• Signal Transduction 25%
• Lung Cancer 25%
• Non-small Cell Lung Cancer (NSCLC) 25%
• Non-responders 25%
• Oncogenic Signaling 25%
• Optimal Alternative 25%
• Targeted Therapy 25%
• Epidermal Growth Factor Receptor 25%
• Targeted Inhibition 25%
• Treatment Trials 25%
• Tyrosine Kinase Inhibitor 25%
• Gefitinib 25%
• Durable Response 25%
• Resistant Disease 25%
• Recurrent Metastatic 25%
• Personalized Cancer Therapy 25%
• Therapeutic Trial 25%
• Alternative Therapeutics 25%
• Unselected Patients 25%
• Advanced Lung Adenocarcinoma 25%
• Primary Resistance 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Chemotherapy 100%
• Pemetrexed 100%
• Lung Adenocarcinoma 100%
• Erlotinib 100%
• Epidermal Growth Factor Receptor Kinase Inhibitor 100%
• Lung Alveolus Cell Carcinoma 100%
• Malignant Neoplasm 25%
• Receptor 25%
• Non Small Cell Lung Cancer 25%
• Lung Cancer 25%
• Epidermal Growth Factor Receptor 25%
• Combination Therapy 25%
• Protein Tyrosine Kinase Inhibitor 25%
• Gefitinib 25%
• Diseases 25%

Medicine and Dentistry

• Pemetrexed 100%
• Lung Adenocarcinoma 100%
• Epidermal Growth Factor Receptor Kinase Inhibitor 100%
• Erlotinib 100%
• Lung Alveolus Cell Carcinoma 100%
• Combination Therapy 25%
• Signal Transduction 25%
• Receptor 25%
• Lung Cancer 25%
• Non Small Cell Lung Cancer 25%
• Epidermal Growth Factor Receptor 25%
• Cancer Therapy 25%
• Targeted Therapy 25%
• Tyrosine-Kinase Inhibitor 25%
• Gefitinib 25%
• Diseases 25%